Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Persistence & Durability Assessment
Are you currently facing high clinical failure rates due to unpredictable in vivo durability and immunogenicity of advanced therapies (Cell, Gene, Biologics)? Our NHP Persistence & Durability Assessment Service helps you streamline preclinical development and quantify therapeutic stability through longitudinal non-human primate models, quantitative imaging, and comprehensive bioanalysis.
NHP Applications in Persistence & Durability Assessment, Validate Long-Term Efficacy, Decisively!
Predicting the long-term safety and efficacy of gene and cell therapies requires translational models that mirror human biology. NHP models provide essential, multi-year data on therapeutic durability, vector clearance, and immune response to reduce IND failure risk.
Overview of NHP Applications
What Are Our Research Areas?
Persistence and durability assessment is the critical preclinical research stage that determines how long a therapeutic agent (such as an AAV vector, an engineered cell product, or a complex biologic) remains functionally active, safe, and effective in vivo. This research is non-negotiable for advanced therapies designed to provide multi-year or curative effects, such as gene therapies for chronic neurological or systemic disorders, or cellular therapies aiming for permanent immune tolerance in transplantation. Our service provides a comprehensive framework for tracking transgene expression levels, cell viability, vector biodistribution, and functional efficacy over extended periods, often exceeding one year, in the most translationally relevant model.
Why Choose Us?
The complexity of human physiology, especially the immune system, necessitates the use of NHPs for robust durability assessment. Creative Biolabs leverages the unique advantages of the NHP model:
- Genetic and Immunological Homology: NHPs share >90% genetic similarity and possess a highly complex, multi-compartment immune system, providing the most accurate prediction of human immunogenicity, ADA development, and vector clearance kinetics.
- Long-Term Study Capability: NHPs allow for the multi-year, longitudinal observation necessary to measure true durability, a time frame impossible to replicate in short-lived models.
- Quantitative In Vivo Metrics: We employ advanced quantitative imaging tools to non-invasively monitor receptor density, cell localization, and transgene expression stability in vivo, providing quantitative data directly linked to functional outcome.
Distributed under Unsplash License, from Unsplash.
Key Applications
NHPs provide the necessary platform to confidently bridge preclinical data to human clinical expectations across multiple advanced modalities.
- Quantifying Long-Term Gene Expression Stability: NHPs enable multi-year tracking of AAV-mediated transgene expression, precisely mapping peak expression kinetics and monitoring the gradual functional decline over 1.5 to 2 years. This allows clients to assess how vector design factors influence in vivo longevity and efficacy.
- Cell Therapy Persistence and Functional Longevity: The NHP model is crucial for assessing the long-term functional viability of engineered cellular product. It accurately models the complex in vivo environment where cells must home, survive, and maintain specific functions long-term to establish persistent therapeutic effects.
- Predicting Systemic Safety and Immunotoxicology: NHPs are the gold standard for assessing the systemic safety and immunotoxicology of advanced therapies, including the potential for delayed immune activation or chronic inflammation over multi-year dosing periods. This is vital for protocols requiring sequential administration or high-titer vector delivery.
- Evaluating Drug Candidates for Chronic Viral Reservoir Control: In models of chronic infectious diseases, NHPs are essential for validating the sustained efficacy of therapeutic vaccines, immune checkpoint blockade (ICB), and cytokine therapies to measure long-term viral control, immune reconstitution, and reduction of the viral reservoir following treatment interruption.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides comprehensive service capabilities to address every aspect of therapeutic persistence and durability assessment. We leverage an integrated approach combining advanced in vivo pharmacology with sophisticated bioanalysis.
| Service Capability | Corresponding Application Area |
| Gene Therapy Models (AAV, Lentivirus) | Longitudinal AAV Expression and Function Assessment. |
| Vector Copy Number (qPCR, ddPCR) | Quantifying Vector Shedding and Biodistribution Over Time. |
| Advanced Therapy Safety (Gene/Cell Therapy) | Multi-Year Immunotoxicity and Systemic Safety Monitoring. |
| Receptor Occupancy (Flow Cytometry) | Tracking Cellular Product Viability and Target Engagement. |
Translational Impact
NHP persistence data is the foundational proof needed for regulatory submission, offering a more reliable early proof of concept than any other model. Our multi-year, quantitative studies significantly reduce the risk of clinical hold or IND failure. By non-invasively quantifying therapeutic durability and providing early detection of potentially dose-limiting immune responses or vector decline, we enable data-driven decisions on dose selection and expected duration of effect. Our long-term NHP studies, provide the necessary confidence to predict drug performance in human trials.
Frequently Asked Questions
Q: What is the minimum duration required for a therapeutically meaningful durability assessment in NHPs?
A: While study length varies by therapeutic modality, we generally recommend a minimum of 12 to 18 months of observation to capture both the peak expression kinetics and the crucial early stages of long-term stability and potential decline. Studies requiring multi-year effects may extend up to 3 years. We guide clients on the optimal duration based on their therapeutic half-life goal.
Q: What are the key data outputs from a long-term durability study required for regulatory submission?
A: We provide a full package including Vector Copy Number (VCN) analysis from multiple tissues (qPCR/ddPCR), PK/TK profiles, comprehensive ADA and Neutralizing Antibody (NAb) assays, and functional endpoint assessment specific to the disease model. All data directly supporting your IND filing.
Q: How does NHP-derived durability data enhance the prediction of clinical human immune response compared to mouse models?
A: NHP data offers superior translational relevance due to highly conserved immune mechanisms and a complex complement system. The NHP model is crucial for identifying low-frequency immunogenic events and predicting the true neutralizing antibody (NAb) profile that is most likely to impact long-term human efficacy, a capability that is often lacking in less homologous preclinical models.
Contact Us
Creative Biolabs delivers validated solutions for the most critical challenge in advanced medicine: therapeutic durability. Our integrated NHP platform ensures comprehensive, multi-year assessment of your gene, cell, or biologic product's long-term safety and efficacy, from peak expression kinetics to sustained functional persistence. For detailed information regarding study design, timelines, and quantitative imaging capabilities, please reach out to our team of scientific experts.